Background: Lung adenocarcinoma (LUAD) has been a leading cause of cancer-related mortality worldwide. Early intervention can significantly improve prognosis. DNA methylation could occur in the early stage of tumor. Comprehensive understanding the epigenetic landscape of early-stage LUAD is crucial in understanding tumorigenesis. Methods: Enzymatic methyl sequencing (EM-seq) was performed on 23 tumors and paired normal tissue to reveal distinct epigenetic landscape, for compared with The Cancer Genome Atlas (TCGA) 450K methylation microarray data. Then, an integrative analysis was performed combined with TCGA LUAD RNA-seq data to identify significant differential methylated and expressed genes. Subsequently, the prognostic risk model was constructed and cellular composition was analyzed. Results: Methylome analysis of EM-seq comparing tumor and normal tissues identified 25 million cytosine-phosphate-guanine (CpG) sites and 30,187 differentially methylated regions (DMR) with a greater number of untraditional types. EM-seq identified a significantly higher number of CpG sites and DMRs compared to the 450K microarray. By integrating the differentially methylated genes (DMGs) with LUAD-related differentially expressed genes (DEGs) from the TCGA database, we constructed prognostic model based on six differentially methylated-expressed genes (MEGs) and verified our prognostic model in GSE13213 and GSE42127 dataset. Finally, cell deconvolution based on the in-house EM-seq methylation profile was used to estimate cellular composition of early-stage LUAD. Conclusions: This study firstly delves into novel pattern of epigenomic DNA methylation and provides a multidimensional analysis of the role of DNA methylation revealed by EM-seq in early-stage LUAD, providing distinctive insights into its potential epigenetic mechanisms.
1 March 2026 in Quantitative Imaging in Medicine and Surgery
Background: Preoperative localization of pulmonary nodules requires multiple computed tomography (CT) scans, making it an urgent problem to address how to effectively reduce radiation damage while maintaining image quality. Artificial intelligence iterative reconstruction (AIIR) can significantly improve the image quality of ultra-low-dose CT (ULDCT). This study aimed to examine the feasibility of using ULDCT-AIIR for the preoperative localization of pulmonary nodules. Methods: This prospective study enrolled 40 consecutive patients with pulmonary nodules who underwent preoperative hook-wire localization under low-dose CT (LDCT). Immediately following the LDCT, an additional ULDCT scan was performed. Images were reconstructed using filtered back projection (FBP) and a hybrid iterative reconstruction (HIR) for both LDCT and ULDCT scans; additionally, AIIR was applied solely to the ULDCT images. Objective parameters measured included image noise, contrast-to-noise ratio (CNR), and the distances between nodules and reference. Subjective image quality was assessed using a 5-point Likert scale, evaluating the visualization of pulmonary nodules, localization grids, needle tips, hook-wires, and complications. Quantitative and qualitative metrics were compared across the reconstruction groups using the Kruskal-Wallis test. Results: The volume CT dose index of ULDCT was 90% lower than that of LDCT (0.22 vs. 2.20 mGy). ULDCT-AIIR showed comparable lung parenchyma noise and CNRnodule-lung to LDCT-HIR (P>0.05), and significantly outperformed other reconstructions (P<0.01). The subjective visualization scores for nodules, localization grids, needle tips, hook-wires, and complications with ULDCT-AIIR were non-inferior to those with LDCT-HIR and significantly superior to most other reconstruction groups (P0.05). Conclusions: ULDCT-AIIR achieves image quality comparable to LDCT-HIR with significantly reduced radiation doses, suggesting its potential as an alternative to LDCT for preoperative pulmonary nodule localization.
25 August 2025 in Eurasian Journal of Medicine and Oncology
Introduction: Translocase of inner mitochondrial membrane 8 homolog B (TIMM8B) is crucial for mitochondrial function, but its role in lung adenocarcinoma (LUAD) remains underexplored. Objective: This study investigates TIMM8B expression patterns, prognostic value, and potential therapeutic implications in LUAD. Methods: The expression and prognostic potential of TIMM8B in LUAD were analyzed using data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression, Gene Expression Omnibus, and Gene Expression Profiling Interactive Analysis 2, with survival analysis performed through Kaplan–Meier plotter. The prognostic value was validated using a LUAD tissue microarray and a nomogram. TIMM8B-related differentially expressed genes were identified using TCGA and LinkedOmics, and were functionally annotated using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases. Immunological features were assessed using TCGA data through the XCELL and tumor immune dysfunction and exclusion algorithms. Associations among TIMM8B, m6A modification, ferroptosis-related genes, and tumor genetic mutations were analyzed using TCGA data. Drug response correlations were explored using the Genomics of Drug Sensitivity in Cancer and Comparative Toxicogenomics databases. TIMM8B-depleted LUAD cell lines were analyzed using ribonucleic acid sequencing and subjected to cell cycle analysis. Results: TIMM8B is overexpressed in multiple cancers, including LUAD. High TIMM8B expression correlates with poorer overall survival in LUAD. A nomogram incorporating TIMM8B and pathological tumor-node-metastasis stage showed reliable predictive performance. TIMM8B-related gene analyses suggest roles in cell adhesion, chromosome segregation, and critical cancer pathways. TIMM8B shapes an immunosuppressive tumor microenvironment in LUAD, affecting immune cell infiltration and immunotherapy response. Elevated TIMM8B expression is associated with TP53 mutations and chemotherapy resistance. Knockdown of TIMM8B in H1299 cells downregulates PD-L1, induces G1 phase arrest, and triggers a chemokine (C-C motif) ligand 2-mediated inflammatory response, highlighting roles in cell cycle regulation and inflammatory pathways. Conclusion: These findings underscore TIMM8B’s multifaceted role in cancer progression and its potential as a prognostic marker and therapeutic target in LUAD.